These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1796 related articles for article (PubMed ID: 32780300)

  • 1. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
    Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
    CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of MS disease-modifying therapies on responses to vaccinations: A review.
    Ciotti JR; Valtcheva MV; Cross AH
    Mult Scler Relat Disord; 2020 Oct; 45():102439. PubMed ID: 32769063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
    Baker D; Amor S; Kang AS; Schmierer K; Giovannoni G
    Mult Scler Relat Disord; 2020 Aug; 43():102174. PubMed ID: 32464584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The COVID-19 pandemic and the use of MS disease-modifying therapies.
    Giovannoni G; Hawkes C; Lechner-Scott J; Levy M; Waubant E; Gold J
    Mult Scler Relat Disord; 2020 Apr; 39():102073. PubMed ID: 32334820
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.
    Baker D; Roberts CAK; Pryce G; Kang AS; Marta M; Reyes S; Schmierer K; Giovannoni G; Amor S
    Clin Exp Immunol; 2020 Nov; 202(2):149-161. PubMed ID: 32671831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.
    Möhn N; Pul R; Kleinschnitz C; Prüss H; Witte T; Stangel M; Skripuletz T
    Front Immunol; 2020; 11():1059. PubMed ID: 32477373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis and COVID-19.
    Mares J; Hartung HP
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Sep; 164(3):217-225. PubMed ID: 32686774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
    ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D
    Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).
    Chang FY; Chen HC; Chen PJ; Ho MS; Hsieh SL; Lin JC; Liu FT; Sytwu HK
    J Biomed Sci; 2020 Jun; 27(1):72. PubMed ID: 32498686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19.
    Xu Y; Baylink DJ; Chen CS; Reeves ME; Xiao J; Lacy C; Lau E; Cao H
    J Transl Med; 2020 Aug; 18(1):322. PubMed ID: 32847594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions.
    Uddin M; Mustafa F; Rizvi TA; Loney T; Suwaidi HA; Al-Marzouqi AHH; Eldin AK; Alsabeeha N; Adrian TE; Stefanini C; Nowotny N; Alsheikh-Ali A; Senok AC
    Viruses; 2020 May; 12(5):. PubMed ID: 32397688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
    Misra DP; Agarwal V; Gasparyan AY; Zimba O
    Clin Rheumatol; 2020 Jul; 39(7):2055-2062. PubMed ID: 32277367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
    Rabenstein M; Thomas OG; Carlin G; Khademi M; Högelin KA; Malmeström C; Axelsson M; Brandt AF; Gafvelin G; Grönlund H; Kockum I; Piehl F; Lycke J; Olsson T; Hessa T
    Eur J Neurol; 2023 Dec; 30(12):3789-3798. PubMed ID: 37522464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology and treatment strategies for COVID-19.
    Kumar M; Al Khodor S
    J Transl Med; 2020 Sep; 18(1):353. PubMed ID: 32933536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years.
    Saad-Roy CM; Wagner CE; Baker RE; Morris SE; Farrar J; Graham AL; Levin SA; Mina MJ; Metcalf CJE; Grenfell BT
    Science; 2020 Nov; 370(6518):811-818. PubMed ID: 32958581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns.
    Zellweger RM; Wartel TA; Marks F; Song M; Kim JH
    Expert Rev Vaccines; 2020 Aug; 19(8):691-698. PubMed ID: 32838605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.
    Prete M; Favoino E; Catacchio G; Racanelli V; Perosa F
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 90.